Select 'Apply to REP' under Program-Specific Elements to apply to this rotation.
Elective Description
The Medical Oncology Service (MOS) and its affiliates conduct translational and clinical research focused on the biology of various tumors and the development of new drugs for treatment. The major functions of the branches are:
- To develop novel therapeutic research strategies for the treatment of cancer and to test those strategies by conducting clinical research in medical oncology across a spectrum of diseases and disease mechanisms;
- To provide clinical care to adult cancer patients enrolled in research protocols, including in-patient and out-patient services, to support the clinical research effort emanating from principal investigators in laboratories and branches across the Center for Cancer Research (CCR); and,
- To train physician-scientists in a laboratory-to-clinic translational research setting to promote the development of their expertise in medical oncology research and to support their board certification by the American Board of Internal Medicine.
The MOS has active programs for clinical and translational research of women's cancers (breast, ovarian and other gynecological malignancies), thoracic malignancies, genitourinary cancers, gastrointestinal cancers, HIV and hematological malignancies such as lymphoma, and multiple myeloma and related precursor conditions.
- The Center for Immunology-Oncology explores fundamental questions of cancer immunotherapy through rigorous preclinical studies and translates these findings into clinical trials with the goal of developing novel therapies for a spectrum of cancer. It is dedicated to coordinated efforts in basic, preclinical and clinical investigations in the areas of immunology, tumor angiogenesis, hematopoiesis, infections in immunocompromised host, antigen discovery, and hematopoietic stem cell transplantation for malignant diseases.
- The Developmental Therapeutics Section focuses on bringing new drugs into clinic by conducting phase 0, I and II clinical trials.
- The Developmental Therapeutics Branch advances novel therapeutic strategies and conducts clinical trials based on cancer-specific genomic, epigenetic and metabolic alterations, drug design, molecular mechanism of drug action to achieve precision medicine.
- The Thoracic and Gastrointestinal Oncology Branch (TGIB) integrates and synergizes multidisciplinary clinical and basic research pertaining to cancers of the lungs and airways, chest cavity (thorax) and gastrointestinal tract.
- The Lymphoid Malignancies Branch focuses on identification of abnormalities to the regulation of the immune response and the definition of molecular disorders that underlie lymphoid malignancies. A major goal of the Branch is to translate fundamental biologic insights into novel treatment of human B and T-cell lymphoid malignancies particularly in molecular subtypes of aggressive B-cell lymphomas.
- The Women's Malignancies Branch (WMB) conducts basic, translational and clinical research on the mechanisms of cancer with emphasis on those that only or primarily affect females such as breast and ovarian cancer.
- The Genitourinary Malignancies Branch focuses on investigating the biology of genitourinary cancers, developing new strategies for treating those cancers, and evaluating these new therapeutic approaches through science-driven clinical research. These clinical trials investigate the novel approaches in immunotherapy, hormonal therapy, chemotherapy combinations, and small-molecule targeted therapy.
- The Vaccine Branch conducts a program of clinical and laboratory research designed to elucidate basic mechanisms of immune response and molecular virology, and to apply these to the design and development of vaccines and immunotherapy for the prevention and treatment of cancer and AIDS, as well as viruses that cause cancer.
- The HIV and AIDS Malignancy Branch conducts laboratory and clinical research in AIDS-related malignancies, HIV disease, viral-induced tumors, and related diseases with the goal of understanding the pathogenesis of these diseases and to develop novel therapies for them based on this understanding.
- The Immune Deficiency Cellular Therapy Program seeks to accelerate process in the treatment of children, adolescents and young adults with genetic diseases of the blood and immune system, collaborating across multiple specialties to synergize disease-specific and gene mutation-specific approaches.
Residents will work alongside clinical staff and follow patients in the out-patient clinics. MOS also organizes a number of departmental and multidisciplinary conferences, which participating residents are expected to attend.
Elective Objectives
- Interact with and follow patients with a broad spectrum of cancer diagnoses
- First-hand experience in the care of patients enrolled in investigational protocols
- Gain insight into the development and conduct of clinical trials
- Complete web-based courses and modules on clinical research
- Observe interactions between basic scientists and clinical staff
- Attend seminars and conferences organized by the MOS and the wider NIH community.
Eligibility
Residents must currently be enrolled, and in good standing, in an Accreditation Council of Graduate Medical Education (ACGME)-accredited internal medicine program in the United States at the time of application for an elective rotation. Foreign medical school graduates, in addition to the above, must have ECFMG certification. A maximum of one resident will be scheduled for each four-week period during the year. Please note: applications MUST be submitted a minimum of three (3) months in advance of the proposed elective rotation start date.
Selection of Applicants
All applicants will be expected to provide COVID-19 vaccination verification.
Elective Director
- Anish Thomas, MBBS, M.D.
Physician Staff
- James Gulley, M.D., Ph.D. (Clinical Director, National Cancer Institute)
- Arun Rajan, M.D (Director, Medical Oncology Services)
- Christine Alewine, M.D., Ph.D.
- Andrea Apolo, M.D.
- Danielle E. Arnold, M.D.
- Gabriella Montenegro Bravo, M.D.
- Alice Chen, M.D.
- Kevin Conlon, M.D.
- Lea C. Cunningham, M.D.
- Jaydira Del Rivero, M.D.
- Dimana Dimitrova, M.D.
- William Douglas Figg, Sr., Pharm.D.
- Charalampos Floudas, M.D., D.M.Sc., M.S.
- Azam Ghafoor, M.D.
- Corina Gonzalez, M.D.
- Tim F. Greten, M.D.
- Udayan Guha, M.B.B.S., Ph.D.
- Raffit Hassan, M.D.
- Dennis Hickstein, M.D.
- Elizabeth Hill, M.D.
- Noa Holtzman, M.D.
- Mustafa Hyder, M.D.
- Kazusa Ishii, M.D., M.P.H.
- Christopher Kanakry, M.D.
- Jennifer Kanakry, M.D.
- Fatima Karzai, M.D.
- Elise Kohn, M.D.
- Robert Kreitman, M.D.
- Rahul Lakhotia, M.D.
- Jung-Min Lee, M.D.
- Vid Leko, M.D.
- Frank Lin, M.D., Ph.D.
- Stanley Lipkowitz, M.D., Ph.D.
- Kathryn Lurain, M.D., M.P.H.
- Ravi Madan, M.D.
- Hoyoung Maeng, M.D.
- Shakun Malik, M.D.
- Meredith Jo McAdams, M.D.
- Christopher Melani, M.D.
- Alain Mian, M.D.
- Lori Minasian, M.D.
- Cecelia Monge-Bonilla, M.D.
- Jagan Muppidi, M.D., Ph.D.
- Scott Norberg, D.O.
- Sung-Yun Pai, M.D.
- Danielle M. Pastor, D.O., Ph.D.
- Steven Pavletic, M.D., Ph.D.
- Ramya Ramaswami, M.B.B.S., M.R.C.P., M.P.H.
- Kamil Rechache, M.D.
- Jason Redman, M.D.
- Mark Roschewski, M.D.
- Nitin Roper, M.D., M.Sc.
- Vassiliki Saalouraa, M.D., Ph.D.
- Nicholas Simon, M.D.
- Ramaprasad Srinivasan, M.D.
- Eva Szabo, M.D.
- Anish Thomas, MBBS, M.D.
- Wyndham Wilson, M.D., Ph.D.
- Robert Yarchoan, M.D.
- Changqing Xie, M.D., Ph.D.
- Chen Zhao, M.D.